Market View 22nd Oct, 2024

View on market: Volatility Prevails, Market is searching for better value

Asian indices started the week on a negative note as they pared some of the gains made on a mixed performance by the New York indices. Most of the U.S. markets closed with mixed prices as investors weighed their quarter results. Shares of key Indian companies got under pressure, as did Kotak Mahindra Bank and Infosys Ltd; benchmark equities slid. But the losses were cushioned by gains from heavyweight counters, including HDFC Bank and Reliance Industries. This means that the investors embark on a risk reservation for an understanding of the earnings and markets, hence creating a negative tone for the week. Major companies’ performance is more important because their performance sets the tone for the general market. In a nutshell, the early trading session turns out to be slightly bearish because traders face mixed corporate earnings and economic indicators.

Economic Calendar:

• USD: S&P Global US Manufacturing PMI (Oct) on 24th October 2024.
• IND: HSBC Manufacturing PMI on 24th October 2024.
• USD: House Price Index (YoY) (Aug) on 29th October 2024.
• IND: Foreign Exchange Reserves (USD) on 25th October 2024.

IPO Watch:

Brokerage Radar:

GOLDMAN SACHS ON ULTRATECH CEMENT:

Maintain Buy; cut target price to Rs 11,720 from Rs 12,430, Q2 Review: Weak profitability, management optimistic on H2 recovery, Price increases will be key to watch as volume share competition is likely to persist, Ultratech is the only Buy in sector od coverage, Bullish on strong balance sheet.

BOFA ON SAPPHIRE FOOD:

Downgrade to Underperform from Neutral; Cut target price to Rs 330 from Rs 336,  It’s tough out there… Risk-reward unfavorable,  Stock rally more than prices in mid-term business upsides, Street earnings estimates may still need a reset lower, Pizza Hut maintains a dominant position in Sri Lanka.

NOMURA ON DR LAL PATHLABS:

Maintain Buy with target price of Rs 3,720,  Expect steady performance despite modest seasonal demand,  Q2 is seasonally strong quarter for the diagnostic industry driven by rise in acute ailments,  Had a relatively high base last year with strong flu/dengue season.

International Markets:

U.S & Europe:

*As per 22^nd October.

Asian markets:

Stocks strong on Chart:

Commodities & Currency:

FIIs & DIIs:

News Update:

Company

Source: Moneycontrol, Bloomberg Quint, Investing Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)Disclosure AppendixAnalyst Certification (For Reports)Vindhyachal Prasad, Elite Wealth Limited, vindhyachal@elitestock.comThe analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.Research ExcerptsThis note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.Company-Specific DisclosuresImportant disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or e-mailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.Options related research:If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.inOther DisclosuresAll research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.Ownership and material conflicts of interest DisclosureElite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.Country Specific DisclosuresIndia – For private circulation only, not for sale.Legal Entities DisclosuresMr. Ravinder Parkash Seth is the Managing Director of Elite Wealth  Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone: 011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.inEWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:

• Reports
• a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;

(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;

• Compensation

(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;(d) EWL  or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;(e) EWL or its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWLProvided that research analyst or research entity shall not be required to make a disclosure as per sub-clauses (c), (d) and (e) of clause (ii) or sub-clauses (a) and (b) of clause (iii) to the extent such disclosure would reveal material non-public information regarding specific potential future investment banking or merchant banking or brokerage services transactions of the subject company.
(4) EWL or its proprietor has never served as an officer, director or employee of the subject company;
(5) EWL has never been engaged in market making activity for the subject company;
(6) EWL shall provide all other disclosures in research report and public appearance as specified by the Board under any other regulations.